Adicet Bio, Inc. (ACET) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boston, MA, 美国. 现任CEO为 Chen Schor.
ACET 拥有 IPO日期为 2018-01-26, 152 名全职员工, 在 NASDAQ Global Market, 市值为 $67.2M.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
